Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M G Bernengo

Showing results (31-40 of 107) with videos related to

Pageof 11
Sort By:
The American Journal of Dermatopathology|August 13, 1998
Immunohistologic findings and adhesion molecule pattern in primary pure cutaneous Rosai-Dorfman disease with xanthomatous featuresP Quaglino, C Tomasini, M Novelli, et al.
Clinical Immunology and Immunopathology|September 1, 1983
Thymostimulin therapy in melanoma patients: correlation of immunologic effects with clinical courseM G Bernengo, P Fra, F Lisa, et al.
Dermatology (Basel, Switzerland)|August 18, 1999
Mycosis fungoides in patients under 20 years of age: report of 7 cases, review of the literature and study of the clinical courseP Quaglino, A Zaccagna, A Verrone, et al.
Journal of Cutaneous Pathology|April 1, 1998
Effects of topical calcipotriol on the expression of adhesion molecules in psoriasisP Savoia, M Novelli, A De Matteis, et al.
The British Journal of Dermatology|February 1, 1993
Soluble interleukin-2 receptor in Sézary syndrome: its origin and clinical applicationM G Bernengo, M T Fierro, M Novelli, et al.
The British Journal of Dermatology|August 1, 1988
Immunomodulation and Sézary syndrome: experience with thymopentin (TP-5)M G Bernengo, G C Doveil, M Meregalli, et al.
Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia|April 1, 1987
[Cutaneous melanoma at the Turin Melanoma Center. II. Risk of metastasis and free interval in relation to the clinical and histological prognostic factors in 502 patients in stage I (1975-1985)]M G Bernengo, G C Doveil, F Lisa, et al.
Cancer|November 15, 1983
The prognostic value of T-lymphocyte levels in malignant melanoma. A five-year follow-upM G Bernengo, F Lisa, M Meregalli, et al.
Leukemia & Lymphoma|January 28, 1999
Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOPM T Fierro, P Quaglino, P Savoia, et al.
Dermatology (Basel, Switzerland)|January 1, 1992
Soluble interleukin-2 receptor, CD4 and CD8 levels in melanoma: a longitudinal studyM T Fierro, F Lisa, M Novelli, et al.
Pageof 11

Showing results (31-40 of 107) with videos related to

Sort By:
Pageof 11
The American Journal of Dermatopathology|August 13, 1998
Immunohistologic findings and adhesion molecule pattern in primary pure cutaneous Rosai-Dorfman disease with xanthomatous featuresP Quaglino, C Tomasini, M Novelli, et al.
Clinical Immunology and Immunopathology|September 1, 1983
Thymostimulin therapy in melanoma patients: correlation of immunologic effects with clinical courseM G Bernengo, P Fra, F Lisa, et al.
Dermatology (Basel, Switzerland)|August 18, 1999
Mycosis fungoides in patients under 20 years of age: report of 7 cases, review of the literature and study of the clinical courseP Quaglino, A Zaccagna, A Verrone, et al.
Journal of Cutaneous Pathology|April 1, 1998
Effects of topical calcipotriol on the expression of adhesion molecules in psoriasisP Savoia, M Novelli, A De Matteis, et al.
The British Journal of Dermatology|February 1, 1993
Soluble interleukin-2 receptor in Sézary syndrome: its origin and clinical applicationM G Bernengo, M T Fierro, M Novelli, et al.
The British Journal of Dermatology|August 1, 1988
Immunomodulation and Sézary syndrome: experience with thymopentin (TP-5)M G Bernengo, G C Doveil, M Meregalli, et al.
Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia|April 1, 1987
[Cutaneous melanoma at the Turin Melanoma Center. II. Risk of metastasis and free interval in relation to the clinical and histological prognostic factors in 502 patients in stage I (1975-1985)]M G Bernengo, G C Doveil, F Lisa, et al.
Cancer|November 15, 1983
The prognostic value of T-lymphocyte levels in malignant melanoma. A five-year follow-upM G Bernengo, F Lisa, M Meregalli, et al.
Leukemia & Lymphoma|January 28, 1999
Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOPM T Fierro, P Quaglino, P Savoia, et al.
Dermatology (Basel, Switzerland)|January 1, 1992
Soluble interleukin-2 receptor, CD4 and CD8 levels in melanoma: a longitudinal studyM T Fierro, F Lisa, M Novelli, et al.
Pageof 11